Subsequent Events (Notes)	3 Months Ended
Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events [Text Block]	SUBSEQUENT EVENTS Drawdown on Revolving Credit Facility and Metrics Contract Services Acquisition In October 2022, the Company acquired Metrics from Mayne Pharma Group Limited for $475 million in cash, subject to customary adjustments. Metrics, based in Greenville, North Carolina, is an oral solids development and manufacturing business specializing in the manufacture of drugs containing highly potent active pharmaceutical ingredients. The Company funded this acquisition with a portion of the proceeds of an October 2022 drawdown of $500 million from its senior secured revolving credit facility. The Company is using the remainder of the drawdown for general corporate purposes. The operations and facility acquired have become part of the Company’s Pharma and Consumer Health segment. The initial accounting for this acquisition is pending. Significant, relevant information needed to complete the initial accounting analysis is not yet available because the valuation of the assets acquired and liabilities assumed is not complete. As a result, determination of these values is not practicable, and the Company will disclose its preliminary allocation of the assets acquired in its next quarterly report.

Subsequent Events (Notes)

3 Months Ended

Sep. 30, 2022

SUBSEQUENT EVENTS

Drawdown on Revolving Credit Facility and Metrics Contract Services Acquisition

In October 2022, the Company acquired Metrics from Mayne Pharma Group Limited for $475 million in cash, subject to customary adjustments. Metrics, based in Greenville, North Carolina, is an oral solids development and manufacturing business specializing in the manufacture of drugs containing highly potent active pharmaceutical ingredients. The Company funded this acquisition with a portion of the proceeds of an October 2022 drawdown of $500 million from its senior secured revolving credit facility. The Company is using the remainder of the drawdown for general corporate purposes.

The operations and facility acquired have become part of the Company’s Pharma and Consumer Health segment. The initial accounting for this acquisition is pending. Significant, relevant information needed to complete the initial accounting analysis is not yet available because the valuation of the assets acquired and liabilities assumed is not complete. As a result, determination of these values is not practicable, and the Company will disclose its preliminary allocation of the assets acquired in its next quarterly report.